Obiettivo MARKinPATH global innovation project aims at undertake the clinical validation of Xylose, after ingestion of Gaxilose, as a Biomarker of intestinal diseases. Currently, the measurement of Xylose after ingestion of Gaxilose is used to evaluate hypolactasia in adults. MARKinPATH is focused to improve the hypolactasia diagnosis; broaden the pathologies to monitor and to extend his use to paediatrics population. MARKinPATH will meet the demand of the EU on and innovation in healthcare, by enhancing diagnosis and management of intestinal pathologies. The resulting solution will also contribute to cost-effective and efficient health expenditure.Xylose-based, after ingestion of Gaxilose, biomarker improves technical features such as specificity and sensitivity with respect to the other tests available in regular clinical practice. Furthermore, alternative methods such as Hydrogen breath test (HBT) and the Lactose tolerance test (LTT) are invasive and have adverse effects that can be very annoying for the patient.Venter Pharma is a highly innovative SME with more than 11 years focused on advanced research, development and commercialization of clinical solutions in this field. Venter Pharma has a relevant Intellectual Capital and an extensive background in these technologies. MARKinPATH would suppose a massive-but-necessary growth and the consolidation of Venter Pharma in the pharmaceutical market. Campo scientifico medical and health sciencesclinical medicinegastroenterologyinflammatory bowel diseasemedical and health sciencesbasic medicineimmunologyautoimmune diseasesmedical and health scienceshealth sciencesnutritionmedical and health sciencesbasic medicinepathologymedical and health sciencesclinical medicinepaediatrics Programma(i) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Argomento(i) PHC-12-2014-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Invito a presentare proposte H2020-SMEInst-2014-2015 Vedi altri progetti per questo bando Bando secondario H2020-SMEINST-1-2014 Meccanismo di finanziamento SME-1 - SME instrument phase 1 Coordinatore VENTER PHARMA S.L. Contribution nette de l'UE € 50 000,00 Indirizzo CALLE AZALEA 1 28109 ALCOBENDAS Spagna Mostra sulla mappa PMI L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione. Sì Regione Comunidad de Madrid Comunidad de Madrid Madrid Tipo di attività Private for-profit entities (excluding Higher or Secondary Education Establishments) Collegamenti Contatta l’organizzazione Opens in new window Partecipazione a programmi di R&I dell'UE Opens in new window Rete di collaborazione HORIZON Opens in new window Costo totale € 71 429,00
